Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease.
To assess the role of androgens in gonadotropin regulation in women, we studied the effects of a pure nonsteroidal antiandrogen, Anandron (Cassenne, Paris, France). Nine normally cycling women (group 1) with acne and/or seborrhoea and nine patients with polycystic ovarian disease (PCOD) (group 2) received Anandron (100 mg twice a day) and a placebo. Both treatments were administered orally, in a cross-over randomized design, for two consecutive cycles (group 1) or months (group 2) separated by one cycle or 1 month. Luteinizing hormone (LH) pulse frequency and amplitude (cluster analysis), basal and gonadotropin-releasing hormone (GnRH)-stimulated plasma LH/follicle-stimulating hormone (FSH) levels were determined on day 5 of each treatment or placebo cycle. On days 5, 10, 20, and 24 of each cycle or month, plasma estradiol (E2), estrone (E1), testosterone (T), dihydrotestosterone (DHT), androstenedione (A), dehydroepiandrosterone sulfate (DHAS), sex hormone-binding globulin (SHBG) levels, and urinary androstanediol glucuronide (3 alpha-diol G) were measured. Plasma progesterone (P) levels were determined on days 20 and 24 of each cycle (group 1) and on days 5, 10, 20, and 24 (group 2). In both groups, seborrhea and acne decreased markedly within the first month and practically disappeared after 2 months of Anandron treatment. No adverse side effects were reported. None of the normal patients had any disturbance of menstrual cycles as assessed by basal body temperature shift, ultrasonography, and plasma P levels. In PCOD patients, cycles remained anovulatory.(ABSTRACT TRUNCATED AT 250 WORDS)
Couzinet
B
B
Service d'Endocrinologie et des Maladies de la Reproduction, (INSERM) U 135, Hopital Bicêtre, Kremlin-Bicêtre, France.
Thomas
G
G
Thalabard
J C
JC
Brailly
S
S
Schaison
G
G
D000328:Adult; D000726:Androgen Antagonists / Q000494:pharmacology*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D048289:Imidazolidines; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000378:metabolism*
D000726:Androgen Antagonists; D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D007093:Imidazoles; D048289:Imidazolidines; C021277:nilutamide; D007986:Luteinizing Hormone